Also trades as: ONC.TO (TSX) · $vol 0M
ONCY NASDAQ
Oncolytics Biotech Inc.
1W: -8.8%
1M: -29.2%
3M: -29.2%
YTD: -36.7%
1Y: -56.1%
3Y: -72.1%
5Y: -71.0%
$0.63
-0.01 (-1.59%)
Weekly Expected Move ±7.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (29)
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
12 Health Care Stocks Moving In Friday's After-Market Session
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Oncolytics Biotech (NASDAQ:ONCY) Trading 1.3% Higher – Here’s Why
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer